CNSDose provides pharmacogenetic testing to guide psychotropic medication selection. Their service analyzes genetic markers to predict individual drug response, enabling clinicians to optimize treatment and reduce adverse events.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients often experience prolonged periods of ineffective treatment and adverse drug reactions due to the trial-and-error approach in psychotropic medication selection. This process can lead to delayed symptom relief and patient dissatisfaction.
Solution
CNSDose offers a pharmacogenetic testing service that analyzes key genes influencing drug metabolism and transport. By utilizing a simple cheek swab, the service generates a comprehensive report detailing how an individual's genetic makeup may affect their response to various medications. This genetic guidance empowers clinicians to select optimal medications and dosages, thereby reducing the likelihood of adverse events and accelerating the time to therapeutic efficacy. The actionable insights provided aim to streamline the treatment selection process for improved patient outcomes.
Target Audience
The primary customers are clinicians, including psychiatrists and general practitioners, who manage patients with mental health conditions and seek to optimize psychotropic medication selection.
Features
- Pharmacogenetic analysis of 19 genes involved in liver enzyme activity (e.g., CYP450 family) and blood-brain barrier transport.
- At-home sample collection kit utilizing a non-invasive cheek swab.
- Proprietary algorithm for generating personalized medication and dosage recommendations based on genetic profiles.
- Report designed for clarity and ease of interpretation by clinicians.
- Secure handling and storage of genetic and personal health data, adhering to privacy regulations.
- Evidence-based recommendations derived from clinical trials and neuroscientific research.